We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
Organon (OGN - Free Report) closed at $8.70 in the latest trading session, marking a +1.05% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.26% for the day. At the same time, the Dow added 0.6%, and the tech-heavy Nasdaq gained 0.25%.
Shares of the pharmaceutical company witnessed a gain of 23.18% over the previous month, beating the performance of the Medical sector with its gain of 0.92%, and the S&P 500's gain of 1.57%.
The investment community will be closely monitoring the performance of Organon in its forthcoming earnings report. The company's upcoming EPS is projected at $0.74, signifying a 17.78% drop compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $1.53 billion, indicating a 3.84% decline compared to the corresponding quarter of the prior year.
OGN's full-year Zacks Consensus Estimates are calling for earnings of $3.78 per share and revenue of $6.24 billion. These results would represent year-over-year changes of -8.03% and 0%, respectively.
Any recent changes to analyst estimates for Organon should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Currently, Organon is carrying a Zacks Rank of #3 (Hold).
From a valuation perspective, Organon is currently exchanging hands at a Forward P/E ratio of 2.19. This represents a discount compared to its industry average Forward P/E of 15.53.
Also, we should mention that OGN has a PEG ratio of 1.7. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical Services was holding an average PEG ratio of 1.92 at yesterday's closing price.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 197, which puts it in the bottom 20% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow OGN in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Organon (OGN) Exceeds Market Returns: Some Facts to Consider
Organon (OGN - Free Report) closed at $8.70 in the latest trading session, marking a +1.05% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.26% for the day. At the same time, the Dow added 0.6%, and the tech-heavy Nasdaq gained 0.25%.
Shares of the pharmaceutical company witnessed a gain of 23.18% over the previous month, beating the performance of the Medical sector with its gain of 0.92%, and the S&P 500's gain of 1.57%.
The investment community will be closely monitoring the performance of Organon in its forthcoming earnings report. The company's upcoming EPS is projected at $0.74, signifying a 17.78% drop compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $1.53 billion, indicating a 3.84% decline compared to the corresponding quarter of the prior year.
OGN's full-year Zacks Consensus Estimates are calling for earnings of $3.78 per share and revenue of $6.24 billion. These results would represent year-over-year changes of -8.03% and 0%, respectively.
Any recent changes to analyst estimates for Organon should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Currently, Organon is carrying a Zacks Rank of #3 (Hold).
From a valuation perspective, Organon is currently exchanging hands at a Forward P/E ratio of 2.19. This represents a discount compared to its industry average Forward P/E of 15.53.
Also, we should mention that OGN has a PEG ratio of 1.7. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical Services was holding an average PEG ratio of 1.92 at yesterday's closing price.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 197, which puts it in the bottom 20% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow OGN in the coming trading sessions, be sure to utilize Zacks.com.